Literature DB >> 36205878

Elevated Serum Ninjurin-1 Is Associated with a High Risk of Large Artery Atherosclerotic Acute Ischemic Stroke.

Nan Dong1,2, Xuan Wu3, Ting Hong4, Xiaozhu Shen5, Xianghong Guo2, Hui Wang1, Liqiang Yu1, Hongru Zhao6, Qi Fang7.   

Abstract

Ninjurin-1 is a novel adhesion molecule which is involved in many inflammatory diseases. Functional blockage of Ninjurin-1 has exerted an atheroprotective effect. The aim of the study is to explore the association between serum Ninjurin-1 and the risk of large artery atherosclerotic acute ischemic stroke. From August 2020 through December 2021, patients with large artery atherosclerotic acute ischemic stroke (LAA-AIS) admitted to the First Hospital Affiliated to Soochow University, and age- and sex-matched controls free of ischemic stroke were recruited. Serum Ninj1 was measured with an enzyme-linked immunosorbent assay. Multivariable logistic regression models were used to calculate the odds ratios and 95% confidence intervals of LAA-AIS associated with serum Ninj1 levels, and receiver operating characteristic (ROC) curves were performed to assess the improvement value of Ninj1 for the prediction of LAA-AIS after adding Ninj1 to established risk factors. Of the 110 patients and 110 age- and sex-matched controls free of ischemic stroke enrolled, serum Ninj1 levels in LAA-AIS patients were significantly higher than that in control group (142.70 ng/ml [IQR: 110.41-163.44] vs 101.62 ng/ml [IQR: 86.63-120.86], p < 0.001). In multivariable analysis, Ninj1 levels were expressed as continuous variable and ordinal variable (tertiles), and it turned out that Ninj1 levels were positively associated with increased risk of LAA-AIS, especially in tertile3 compared with tertile1 (adjusted OR = 12.567, 95%CI: 5.148-30.678, p < 0.001), and the adjusted odds OR per 10 ng/ml increment was 1.541, 95%CI: 1.348-1.763, p < 0.001. Furthermore, adding Ninj1 to a multivariate logistic model including conventional risk factors associated LAA-AIS improved the area under ROC curves from 0.787 to 0.874. Elevated circulating levels of Ninj1 were associated with increased risk of LAA-AIS, indicating that serum Ninj1 may act as a predictor independent of established conventional risk factors.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute ischemic stroke; Atherosclerotic; Ninjurin-1; Risk factor

Year:  2022        PMID: 36205878     DOI: 10.1007/s12975-022-01077-6

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.800


  23 in total

1.  Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions.

Authors:  Igal Ifergan; Hania Kebir; Simone Terouz; Jorge I Alvarez; Marc-André Lécuyer; Steve Gendron; Lyne Bourbonnière; Ildiko R Dunay; Alain Bouthillier; Robert Moumdjian; Adriano Fontana; Arsalan Haqqani; Armelle Klopstein; Marco Prinz; Rubèn López-Vales; Thomas Birchler; Alexandre Prat
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

2.  Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth.

Authors:  T Araki; J Milbrandt
Journal:  Neuron       Date:  1996-08       Impact factor: 17.173

3.  Contribution of Ninjurin1 to Toll-like receptor 4 signaling and systemic inflammation.

Authors:  Carla Jennewein; Ralf Sowa; Anne C Faber; Madlen Dildey; Andreas von Knethen; Patrick Meybohm; Bertram Scheller; Stefan Dröse; Kai Zacharowski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

4.  Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.

Authors:  Aernoud T L Fiolet; Tjerk S J Opstal; Arend Mosterd; John W Eikelboom; Sanjit S Jolly; Anthony C Keech; Peter Kelly; David C Tong; Jaimie Layland; Stefan M Nidorf; Peter L Thompson; Charley Budgeon; Jan G P Tijssen; Jan H Cornel
Journal:  Eur Heart J       Date:  2021-03-26       Impact factor: 29.983

5.  NINJ1 mediates plasma membrane rupture during lytic cell death.

Authors:  Nobuhiko Kayagaki; Opher S Kornfeld; Bettina L Lee; Irma B Stowe; Karen O'Rourke; Qingling Li; Wendy Sandoval; Donghong Yan; Jing Kang; Min Xu; Juan Zhang; Wyne P Lee; Brent S McKenzie; Gözde Ulas; Jian Payandeh; Merone Roose-Girma; Zora Modrusan; Rohit Reja; Meredith Sagolla; Joshua D Webster; Vicky Cho; T Daniel Andrews; Lucy X Morris; Lisa A Miosge; Christopher C Goodnow; Edward M Bertram; Vishva M Dixit
Journal:  Nature       Date:  2021-01-20       Impact factor: 49.962

Review 6.  Atherosclerosis: Recent developments.

Authors:  Johan L M Björkegren; Aldons J Lusis
Journal:  Cell       Date:  2022-05-02       Impact factor: 66.850

7.  Ninjurin1 deficiency attenuates susceptibility of experimental autoimmune encephalomyelitis in mice.

Authors:  Bum Ju Ahn; Hoang Le; Min Wook Shin; Sung-Jin Bae; Eun Ji Lee; Hee-Jun Wee; Jong-Ho Cha; Hyo-Jong Lee; Hye Shin Lee; Jeong Hun Kim; Chang-Yeon Kim; Ji Hae Seo; Eng H Lo; Sejin Jeon; Mi-Ni Lee; Goo Taeg Oh; Guo Nan Yin; Ji-Kan Ryu; Jun-Kyu Suh; Kyu-Won Kim
Journal:  J Biol Chem       Date:  2013-12-17       Impact factor: 5.157

8.  Ninjurin1 suppresses metastatic property of lung cancer cells through inhibition of interleukin 6 signaling pathway.

Authors:  Yeong-Su Jang; Ju-Hee Kang; Jong Kyu Woo; Hwan Mook Kim; Jong-Ik Hwang; Sang-Jin Lee; Ho-Young Lee; Seung Hyun Oh
Journal:  Int J Cancer       Date:  2016-02-16       Impact factor: 7.396

9.  Ninjurin1 Plays a Crucial Role in Pulmonary Fibrosis by Promoting Interaction between Macrophages and Alveolar Epithelial Cells.

Authors:  Seungho Choi; Jong Kyu Woo; Yeong-Su Jang; Ju-Hee Kang; Jong-Ik Hwang; Je Kyung Seong; Yeo Sung Yoon; Seung Hyun Oh
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

Review 10.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.

Authors:  Gregory A Roth; George A Mensah; Catherine O Johnson; Giovanni Addolorato; Enrico Ammirati; Larry M Baddour; Noël C Barengo; Andrea Z Beaton; Emelia J Benjamin; Catherine P Benziger; Aimé Bonny; Michael Brauer; Marianne Brodmann; Thomas J Cahill; Jonathan Carapetis; Alberico L Catapano; Sumeet S Chugh; Leslie T Cooper; Josef Coresh; Michael Criqui; Nicole DeCleene; Kim A Eagle; Sophia Emmons-Bell; Valery L Feigin; Joaquim Fernández-Solà; Gerry Fowkes; Emmanuela Gakidou; Scott M Grundy; Feng J He; George Howard; Frank Hu; Lesley Inker; Ganesan Karthikeyan; Nicholas Kassebaum; Walter Koroshetz; Carl Lavie; Donald Lloyd-Jones; Hong S Lu; Antonio Mirijello; Awoke Misganaw Temesgen; Ali Mokdad; Andrew E Moran; Paul Muntner; Jagat Narula; Bruce Neal; Mpiko Ntsekhe; Glaucia Moraes de Oliveira; Catherine Otto; Mayowa Owolabi; Michael Pratt; Sanjay Rajagopalan; Marissa Reitsma; Antonio Luiz P Ribeiro; Nancy Rigotti; Anthony Rodgers; Craig Sable; Saate Shakil; Karen Sliwa-Hahnle; Benjamin Stark; Johan Sundström; Patrick Timpel; Imad M Tleyjeh; Marco Valgimigli; Theo Vos; Paul K Whelton; Magdi Yacoub; Liesl Zuhlke; Christopher Murray; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2020-12-22       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.